https://cf-clinical-studies.com/
CF Phase 1b RCT2100
Find more information about the study, investigational medicine, and how you, or someone you know, can participate.
phase 1bcf
https://www.biospace.com/imugene-completes-phase-1b-cancer-vaccine-trial-recruitment
Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment - BioSpace
Sep 12, 2018 - Imugene Limited today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.
phase 1bcancer vaccinetrial recruitmentimugenecompletes
https://www.globenewswire.com/de/news-release/2024/04/18/2865826/0/en/barinthus-bio-announces-topline-data-from-phase-1b-2-apollo-trial-of-vtp-200-in-persistent-high-risk-human-papillomavirus-hpv-infections.html
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001)....
phase 1bbarinthusbioannouncestopline
https://www.biospace.com/neumora-therapeutics-announces-initiation-of-phase-1b-study-of-nmra-511-for-treatment-of-alzheimer-s-disease-agitation
Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of...
Jun 20, 2024 - Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical...
phase 1b
https://www.globenewswire.com/de/news-release/2024/04/18/2865826/0/en/Barinthus-Bio-Announces-Topline-Data-from-Phase-1b-2-APOLLO-Trial-of-VTP-200-in-Persistent-High-Risk-Human-Papillomavirus-HPV-Infections.html
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001)....
phase 1bbarinthusbioannouncestopline
https://www.globenewswire.com/news-release/2024/04/18/2865826/0/en/barinthus-bio-announces-topline-data-from-phase-1b-2-apollo-trial-of-vtp-200-in-persistent-high-risk-human-papillomavirus-hpv-infections.html
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO
Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced topline final data from the APOLLO trial (also known as HPV001)....
phase 1bbarinthusbioannouncestopline
https://www.cuanschutz.edu/coronavirus/updates/archives/colorado-opens-phase-1b3-adds-1b4
Colorado Opens Phase 1B.3, Adds 1B.4 | University of Colorado Anschutz Medical Campus
phase 1b
https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2022-0231.html
Phase 1b of lurbinectedin in combination with weekly paclitaxel and bevacizumab in...
To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.
phase 1blurbinectedin
https://www.biospace.com/tiumbio-presents-phase-1b-interim-results-for-tu2218-in-combination-with-pembrolizumab-at-asco-2024-annual-meeting
TiumBio Presents Phase 1b Interim Results for TU2218 in Combination with Pembrolizumab at ASCO 2024...
Jun 3, 2024 - TiumBio Co., Ltd. announced interim results from the Phase 1b clinical trial of TU2218 in combination with pembrolizumab at the 2024 American Society of...
https://www.biospace.com/cerevel-therapeutics-initiates-phase-1b-clinical-trial-of-cvl-231-a-m4-selective-positive-allosteric-modulator-in-development-for-the-treatment-of-schizophrenia
Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive...
Oct 22, 2019 - Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today it has dosed the first...
https://www.biospace.com/biolinerx-announces-initiation-of-phase-1b-clinical-trial-in-patients-with-acute-respiratory-distress-syndrome-ards-secondary-to-covid-19-and-other-respiratory-viral-infections
BioLineRx Announces Initiation of Phase 1b Clinical Trial in Patients with Acute Respiratory...
Nov 18, 2020 - - Investigator-initiated study, led by Wolfson Medical Center, to evaluate Motixafortide in up to 25 patients hospitalized with ARDS - - Results of preliminary...
https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-the-completion-of-a-phase-1b-multiple-ascending-dose-study-of-ads051-for-the-treatment-of-moderately-to-severely-active-ulcerative-colitis-301838633.html
Adiso Therapeutics Announces the Completion of a Phase 1b Multiple Ascending Dose Study of ADS051...
/PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines targeting chronic inflammatory diseases today...
https://www.fox5dc.com/news/marylands-phase-1b-covid-19-vaccination-plan-to-include-teachers-residents-over-75
Maryland's Phase 1B COVID-19 vaccination plan to include teachers, residents over 75 | FOX 5 DC
Maryland Governor Larry Hogan announced Tuesday a new phase in the state's COVID-19 vaccination plan, which will include teachers and residents over the age of...
https://www.biospace.com/transgene-to-present-phase-1b-2-trial-results-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers-at-esmo-io-2020
Transgene to Present Phase 1b/2 Trial Results of TG4001 in Combination with avelumab in Advanced...
Dec 3, 2020 - Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, will present the Phase 1b/2 trial results of...
https://www.newsfilecorp.com/release/180828
Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients...
Encinitas, California--(Newsfile Corp. - September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final...
https://www.benzinga.com/news/26/02/50732791/agenus-data-from-phase-1b-c-800-01-study-evaluating-botensilimab-shows-survival-with-bot-bal-associa
Agenus Data From Phase 1b C-800-01 Study Evaluating Botensilimab Shows Survival With BOT+BAL...
Feb 19, 2026 - Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial...
https://www.biospace.com/synthetic-biologics-inc-announces-first-patient-dosed-in-phase-1b-clinical-trial-of-syn-004-for-the-prevention-of-c-difficile-infection
Synthetic Biologics, Inc. Announces First Patient Dosed In Phase 1b Clinical Trial Of SYN-004 For...
https://www.biospace.com/press-releases/armata-pharmaceuticals-announces-positive-topline-data-from-the-phase-1b-2a-disarm-study-of-intravenously-administered-ap-sa02-in-complicated-staphylococcus-aureus-bacteremia
Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of...
https://www.biospace.com/89bio-presents-updated-clinical-data-from-positive-phase-1b-2a-study-of-bio89-100-in-nash-at-aasld-s-the-liver-meeting-2020
89bio Presents Updated Clinical Data from Positive Phase 1b/2a Study of BIO89-100 in NASH at...
Nov 13, 2020 - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...
https://www.businesswire.com/news/home/20230323005287/en/GRIN-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1B-Clinical-Trial-with-Radiprodil-for-Treatment-of-GRIN-related-Disorders
GRIN Therapeutics Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for...
GRIN Therapeutics Inc. Announces First Patient Dosed in Phase 1B Clinical Trial with Radiprodil for Treatment of GRIN-related Disorders.
https://www.cbsnews.com/chicago/news/illinois-enters-phase-1b-of-covid-19-vaccinations-find-where-to-sign-up-here/
Illinois To Enter Phase 1B Of COVID-19 Vaccinations, But Some Sign Ups Need Adjusting - CBS Chicago
Almost 2 million people in the state 65 and older or essential workers will be eligible for the COVID-19 vaccine Monday.
https://www.constructiondive.com/news/ca-rail-authority-changes-route-adds-1b-to-first-phase/417998/
CA rail authority changes route, adds $1B to first phase | Construction Dive
Tutor Perini has already submitted a $51.7 million change order and is pricing out at least two more related to project delays.
https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-previously-announced-data-from-the-phase-1b-clinical-trial-evaluating-low-dose-lti-03-in-idiopathic-pulmonary-fibrosis-ipf-at-the-22nd-international-colloquium-on-lung-and-airway-fibrosis-302274268.html
Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial...
/PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to...
https://www.prnewswire.com/news-releases/zucara-therapeutics-doses-first-patients-in-phase-1b-trial-of-zt-01-301342713.html
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01
/PRNewswire/ - Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia...
in phase
https://www.sante.fr/essais-cliniques/2024-518780-36-00/a-phase-1b-open-label-pilot-study-of-cln-978-for-the-treatment-of-moderate-to-severe-systemic-lupus-erythematosus-sle
A Phase 1b, Open-label, Pilot Study of CLN-978 for the Treatment of Moderate to Severe Systemic...
https://www.biospace.com/arvinas-and-pfizer-announce-updated-clinical-data-from-phase-1b-trial-of-vepdegestrant-in-combination-with-palbociclib-ibrance
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in...
May 16, 2024 - Arvinas, Inc. and Pfizer Inc. announced updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant, an investigational oral PROteolysis...
https://www.biospace.com/evelo-biosciences-reports-positive-topline-clinical-data-in-phase-1b-trial-of-edp1815-in-atopic-dermatitis
Evelo Biosciences Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic...
Dec 9, 2020 - Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the...
https://www.financialcontent.com/article/bizwire-2026-5-7-drug-farm-to-present-ophthalmologic-and-cns-findings-from-phase-1b-study-of-first-in-class-alpk1-inhibitor-df-003-in-rosah-syndrome-at-arvo-2026
Drug Farm to Present Ophthalmologic and CNS Findings from Phase 1b Study of First-in-Class ALPK1...
Drug Farm today announced ophthalmologic and central nervous system (CNS) findings from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor,...
https://www.globenewswire.com/news-release/2025/02/12/3025403/0/en/Bio-Path-Holdings-Provides-Update-from-Phase-1-1b-Clinical-Trial-of-BP1002-for-Treatment-of-Refractory-Relapsed-Acute-Myeloid-Leukemia.html
Bio-Path Holdings Provides Update from Phase 1/1b Clinical
Study Progresses to Fourth Higher 90 mg/m2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count...
phase 1biopathholdingsprovides
https://www.adventhealth.com/institute/adventhealth-research-institute/clinical-cancer-research/clinical-trials/3850-op-1250-003-a-phase-1b-open-label-multicenter-study-op-1250-combination-cdk4-6-inhibitor-ribociclib
OP-1250-003 - A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6...
Participants will be invited to take part in this clinical research study if they have been treated for hormone receptor (HR)-positive and human epidermal...
https://www.finanznachrichten.de/nachrichten-2026-03/68033916-c4-therapeutics-inc-c4-therapeutics-announces-first-patient-dosed-in-phase-1b-trial-of-cemsidomide-in-combination-with-elranatamab-elrexfio-for-r-399.htm
C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of...
WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to...
https://www.prnewswire.com/news-releases/phoenix-molecular-designs-receives-fda-clearance-to-begin-phase-11b-clinical-trial-with-pmd-026-a-first-in-class-rsk-inhibitor-targeting-advanced-breast-cancer-300922795.html
Phoenix Molecular Designs Receives FDA Clearance to Begin Phase 1/1b Clinical Trial with PMD-026, a...
/PRNewswire/ -- Phoenix Molecular Designs (PhoenixMD), a clinical stage biotechnology company developing precise cancer therapeutics targeting essential...
https://www.biospace.com/sfa-therapeutics-announces-fda-clearance-for-amendment-to-extend-phase-1b-trial-of-sfa-002-for-psoriasis
SFA Therapeutics Announces FDA Clearance for Amendment to Extend Phase 1b Trial of SFA-002 for...
Jan 11, 2023 - SFA Therapeutics, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with an extension to the...
https://www.mskcc.org/cancer-care/clinical-trials/24-228
A Phase 1b/2 Study of Ifinatamab Deruxtecan Plus Atezolizumab With or Without Carboplatin in People...
Full Title A Phase 1b/2, Multicenter, Open-label Study of Ifinatamab Deruxtecan (I-DXd), A B7-H3 Antibody-Drug Conjugate (ADC), in Combination with...
https://www.biospace.com/press-releases/enterobiotix-to-present-results-from-phase-1b-trial-in-liver-cirrhosis-at-easl-congress-2025
EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025 -...
https://www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/doorstop-interview-about-phase-1b-of-the-covid-vaccine-rollout
Doorstop interview about phase 1B of the COVID vaccine rollout | Health, Disability and Ageing...
Nov 16, 2022 - Read the transcript of the press conference with Minister Hunt, Professor Brendan Murphy, and Professor John Skerritt in Canberra on 17 March with an update on...
https://www.fiercebiotech.com/biotech/third-harmonic-bio-raises-105-million-series-b-push-hives-treatment-through-phase-1b
Third Harmonic Bio raises $105M in series B to push hives treatment through phase 1b | Fierce...
Feb 16, 2022 - Third Harmonic Bio raised more than $105 million from its series B round, money the company says will be used to further deve
https://www.biospace.com/adastra-pharmaceuticals-announces-positive-interim-data-from-phase-1b-clinical-trial-of-zotiraciclib-in-the-treatment-of-recurrent-malignant-gliomas
Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of...
Jun 4, 2019 - National Cancer Institute (NCI) Study Designed to Investigate Zotiraciclib in Combination with Temozolomide (TMZ) Presented During Poster Session at ASCO 2019
https://docs.google.com/document/d/19HVTM3NYiSoaKvKFwSzxYrcnjzqL14KjzOn4tx0SHlU/edit
Guidance for Phase 1A and 1B Occupations - Google Docs
Guidance for COVID-19 Vaccine Phased Allocation Phase 1A and 1B.1 Occupations - Healthcare Workers and First Responders Last updated December 2020 General This...
phase 1aguidance1boccupationsgoogle
https://www.businesswire.com/news/home/20231116001299/en/PureTech-Founded-Entity-Karuna-Therapeutics-Announces-Positive-Results-from-Phase-1b-Ambulatory-Blood-Pressure-Monitoring-Trial-of-KarXT-in-Schizophrenia
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory...
PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Ph 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
karuna therapeutics
https://www.biospace.com/kiora-pharmaceuticals-receives-investigational-new-drug-application-approval-to-expand-phase-1b-study-of-kio-301-in-inherited-retinal-diseases-to-enroll-patients-with-choroideremia-and-additional-patients-with-late-stage-retinitis-pigmentosa
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b...
Oct 3, 2023 - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional patients in the...
investigational new drug
https://www.news-medical.net/news/2008/11/24/43340.aspx
Medarex starts phase 1b clinical trial with MDX-1106 for the treatment of cancer
Nov 25, 2008 - Medarex, Inc. has announced it has initiated a Phase 1b clinical trial for MDX-1106 (ONO-4538: development code of Ono Pharmaceutical Co., Ltd.), a fully human...
https://www.yalemedicine.org/clinical-trials/biocryst-bcx17725-101
A PHASE 1/1B STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND IMMUNOGENICITY OF...
https://www.biospace.com/theravance-biopharma-announces-data-from-phase-1b-study-of-td-1473-to-be-featured-in-oral-presentation-at-digestive-disease-week-ddw-2019
Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 to be Featured in Oral...
May 15, 2019 - Presentation to Highlight Positive Data Demonstrating Clinical and Biomarker Activity Suggesting Localized Target Engagement and Minimal Systemic Exposure...
https://www.biospace.com/adaptive-phage-therapeutics-announces-strategic-agreement-with-arlg-to-support-phase-1b-2-cystic-fibrosis-study
Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic...
Nov 2, 2021 - Adaptive Phage Therapeutics, Inc. (APT), today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to...
https://investingnews.com/daily/life-science-investing/biotech-investing/aprea-therapeutics-presents-data-from-phase-1b2-clinical-trial-of-apr-246/
Aprea Therapeutics Presents Data from Phase 1b/2 Clinical Trial of APR-246 | INN
Jan 2, 2026 - Aprea Therapeutics (NASDAQ:APRE) has announced preliminary results of its French Phase 1b/2 clinical trial of APR-246 in mutant myelodysplastic syndromes (MDS)...
https://www.biospace.com/edgewise-therapeutics-to-report-phase-1b-topline-results-of-edg-5506-in-individuals-with-becker-muscular-dystrophy-bmd-on-january-5-2022-and-initiates-arch-follow-on-open-label-bmd-study
Edgewise Therapeutics to Report Phase 1b Topline Results of EDG-5506 in Individuals with Becker...
Dec 15, 2021 - Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for...
https://www.phillyvoice.com/philly-covid-19-vaccine-eligibility-seniors-65-over/
COVID-19 Vaccine and Philly: Residents 65 and up now eligible in Phase 1B | PhillyVoice
Mar 10, 2021 - Philadelphia residents ages 65 and older are now eligible to receive a COVID-19 vaccine in Phase 1B, health department officials announced Wednesday. The...
covid 19 vaccine
https://finviz.com/news/94440/i-mab-presents-positive-givastomig-phase-1b-dose-escalation-data-in-combination-with-immunochemotherapy-in-patients-with-1l-gastric-cancers-at-esmo-gi-2025
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with...
Stock screener for investors and traders, financial visualizations.
https://www.biospace.com/press-releases/panther-initiates-phase-1b-clinical-trial-of-absorbable-long-lasting-high-dose-chemotherapy-patch-for-pancreatic-cancer
PanTher Initiates Phase 1b Clinical Trial of Absorbable, Long-Lasting, High-Dose Chemotherapy Patch...
https://www.biospace.com/samus-therapeutics-announces-presentation-of-phase-1b-study-evaluating-orally-administered-pu-h71-with-ruxolitinib-in-myelofibrosis-at-the-ash-2019-annual-meeting
Samus Therapeutics Announces Presentation of Phase 1b Study Evaluating Orally Administered PU-H71...
Dec 9, 2019 - Samus Therapeutics, Inc. ("Samus" or the "Company"), today announced a poster presentation addressing the Company's Phase 1 study evaluating orally...
https://www.biospace.com/nektar-therapeutics-announces-phase-1b-data-for-novel-t-regulatory-cell-stimulator-nktr-358-ly3471851-in-patients-with-atopic-dermatitis
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358...
https://www.biospace.com/adocia-and-eli-lilly-initiate-phase-1b-study-evaluating-ultra-rapid-insulin-biochaperone-lispro-u100-in-healthy-japanese-subjects
Adocia And Eli Lilly Initiate Phase 1b Study Evaluating Ultra-Rapid Insulin BioChaperone Lispro...
https://www.biospace.com/press-releases/akamis-bio-announces-enrollment-of-first-patient-in-phase-1b-fortress-trial-of-ng-350a-in-patients-with-locally-advanced-rectal-cancer
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients...
https://www.biospace.com/crescendo-biologics-secures-32m-and-announces-expansion-of-cb307-phase-1b-trial-in-psma-solid-tumours
Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid...
Jul 24, 2023 - Crescendo Biologics Ltd today announces that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab...
https://www.biospace.com/press-releases/moleculin-releases-on-demand-kol-webcast-to-discuss-data-from-its-phase-1b-2-study-of-annamycin-for-the-treatment-of-soft-tissue-sarcoma-sts-lung-metastases-mb-107
Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for...
https://www.prnewswire.com/news-releases/gracell-biotechnologies-announces-fda-clearance-of-the-ind-application-for-phase-1b2-clinical-trial-of-fastcar-t-gc012f-for-the-treatment-of-relapsedrefractory-multiple-myeloma-301738212.html
Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical...
/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...
https://www.biospace.com/press-releases/tectonic-therapeutic-presents-complete-results-for-positive-phase-1b-clinical-trial-of-tx45-in-patients-with-group-2-pulmonary-hypertension-in-hfpef-in-late-breaking-presentation-at-esc-heart-failure-2025
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in...
https://finviz.com/news/267943/novabridge-presents-positive-givastomig-dose-expansion-data-from-the-phase-1b-combination-study-in-patients-with-1l-metastatic-gastric-cancer
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in...
Stock screener for investors and traders, financial visualizations.
https://www.businesswire.com/news/home/20250512968719/en/Lantern-Pharma-Secures-FDA-Clearance-for-Planned-Phase-1b2-Trial-of-LP-184-in-Biomarker-Defined-Treatment-Resistant-NSCLC-Patients-with-High-Unmet-Clinical-Need
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined,...
Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platf...
https://www.biospace.com/disc-presents-initial-positive-data-from-ongoing-phase-1b-2-trial-of-disc-0974-in-patients-with-myelofibrosis-mf-and-anemia-at-the-65th-american-society-of-hematology-ash-annual-meeting
Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with...
Dec 11, 2023 - Disc Medicine, Inc. (NASDAQ:IRON), today announced data from initial dose cohorts of its ongoing phase 1b/2 study of DISC-0974, a monoclonal antibody designed...
https://www.businesswire.com/news/home/20240318622704/en/AliveGen-Announces-Successful-Completion-of-Phase-1b-Multiple-Ascending-Dose-Clinical-Trial-for-ALG-801
AliveGen Announces Successful Completion of Phase 1b Multiple-Ascending Dose Clinical Trial for...
AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company dedicated to developing first-in-class and best-in-class therapeutics for treating m...
https://www.biospace.com/viracta-therapeutics-announces-interim-data-from-phase-1b-2-clinical-trial-of-nana-val-in-patients-with-epstein-barr-virus-positive-solid-tumors-that-show-confirmed-tumor-responses-at-higher-dose-levels
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients...
Dec 4, 2023 - Viracta Therapeutics, Inc. today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with...
https://www.biospace.com/regulus-therapeutics-announces-first-patient-dosed-in-third-cohort-of-phase-1b-multiple-ascending-dose-mad-clinical-trial-of-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending...
Nov 2, 2023 - Regulus Therapeutics Inc. today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.
https://www.businesswire.com/news/home/20260417849986/en/Drug-Farm-to-Present-Positive-Phase-1b-Data-for-First-in-Class-ALPK1-Inhibitor-DF-003-in-ROSAH-Syndrome-at-IMMUNOLOGY2026
Drug Farm to Present Positive Phase 1b Data for First-in-Class ALPK1 Inhibitor DF-003 in ROSAH...
Drug Farm today announced that preliminary immunologic and clinical results from its Phase 1b study of DF-003, a first-in-class oral ALPK1 inhibitor, will be...
https://www.health.gov.au/resources/publications/priority-groups-for-covid-19-vaccination-program-phase-1b
Priority groups for COVID-19 Vaccination Program: Phase 1b | Australian Government Department of...
Nov 16, 2022 - This presentation shows who will be vaccinated for COVID-19 under Phase 1b, based on recommendations by the Australian Technical Advisory Group on Immunisation.
covid 19 vaccination
https://finviz.com/news/186780/rigel-announces-first-patient-enrolled-in-the-dose-expansion-phase-of-its-phase-1b-study-of-r289-in-patients-with-lower-risk-mds
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in...
Stock screener for investors and traders, financial visualizations.
https://www.prnewswire.com/news-releases/amplifier-therapeutics-a-cambrian-bio-pipeline-company-doses-first-patients-in-phase-1b-clinical-trial-and-closes-new-financing-from-future-ventures-and-ra-capital-management-301958646.html
Amplifier Therapeutics, a Cambrian Bio pipeline company, doses first patients in Phase 1B clinical...
/PRNewswire/ -- Amplifier Therapeutics, a Cambrian Bio pipeline company, today announced the dosing of the first patient in the company's Phase 1B clinical...
https://www.biospace.com/press-releases/sfa-therapeutics-announces-positive-phase-1b-data-of-sfa-002-in-mild-to-moderate-psoriasis
SFA Therapeutics Announces Positive Phase 1b Data of SFA-002 in Mild-to-Moderate Psoriasis -...
https://www.biospace.com/lexaria-awards-cro-contract-for-upcoming-u-s-phase-1b-hypertension-study
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study - BioSpace
Apr 24, 2023 - Lexaria Bioscience Corp. announces it has awarded the contract for clinical research organization ("CRO") services for its expected upcoming Food and Drug...
https://www.prnewswire.co.uk/news-releases/heptares-announces-positive-results-from-phase-1b-clinical-trial-with-htl9936-a-first-in-class-selective-muscarinic-m1-receptor-agonist-for-improving-cognition-in-dementia-and-schizophrenia-568277261.html
Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class...
/PRNewswire/ -- Demonstrates changes in brain activity, therapeutic window and M1 receptor selectivity Heptares Therapeutics ("Heptares"), the wholly-owned...
https://www.biospace.com/calico-life-sciences-announces-first-participant-dosed-in-phase-1b-clinical-study-evaluating-abbv-cls-7262-for-the-treatment-of-vanishing-white-matter-disease
Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating...
Apr 26, 2023 - Calico Life Sciences LLC today announced that the first participant has been dosed in a Phase 1b clinical trial, (study M23-523; NCT05757141), evaluating the...
calico life sciences
https://www.biospace.com/oric-pharmaceuticals-announces-first-patients-dosed-across-three-expansion-cohorts-in-phase-1b-trial-of-oric-114-in-patients-with-mutated-nsclc
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b...
Apr 15, 2024 - ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic...
https://www.businesswire.com/news/home/20260401530565/en/Newleos-Announces-Dosing-of-First-Participant-in-U.K.-Phase-1b-Study-of-NTX-1955-in-Generalized-Anxiety-Disorder
Newleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized...
Newleos Therapeutics, Inc., a clinical-stage biotechnology company developing innovative treatments for neuropsychiatric disorders, today announced that the ...
https://www.businesswire.com/news/home/20240520638624/en/Anokion-Announces-New-Clinical-Data-from-the-Phase-1b2-ACeD-it-Trial-Supporting-KAN-101-as-a-Potential-Disease-Modifying-Treatment-for-Celiac-Disease
Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a...
Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced additional fa...
https://finviz.com/news/89260/i-mab-highlights-positive-givastomig-phase-1b-dose-escalation-data-in-combination-with-immunochemotherapy-in-patients-with-1l-gastric-cancers-at-esmo-gi-2025
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with...
Stock screener for investors and traders, financial visualizations.
https://www.prweb.com/releases/tragara_reports_interim_results_of_phase_1b_study_of_tg02_and_carfilzomib_in_multiple_myeloma/prweb12376938.htm
Tragara Reports Interim Results of Phase 1b Study of TG02 and Carfilzomib in Multiple Myeloma
San Diego, California (PRWEB) December 06, 2014 -- Tragara Pharmaceuticals, Inc. today reported early clinical observations from an ongoing Phase 1b trial of...
https://www.dana-farber.org/clinical-trials/25-076
A phase 1b study of BCL-XL degrader DT2216 in combination with weekly paclitaxel in recurrent...
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably...
https://www.biospace.com/new-clinical-data-presented-from-phase-1b-study-of-nktr-358-a-novel-t-regulatory-cell-stimulator-at-2020-american-college-of-rheumatology-acr-congress
New Clinical Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator,...
Nov 4, 2020 - Nektar Therapeutics (NASDAQ:NKTR) announced the presentation of additional clinical data from the Phase 1b study evaluating multiple ascending doses of...
https://www.jnj.com/media-center/press-releases/early-deep-durable-responses-of-ciltacabtagene-autoleucel-cilta-cel-observed-in-phase-1b-2-cartitude-1-study-show-potential-of-bcma-car-t-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma
Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2...
Feb 14, 2024 - Combined results from Phase 1b/2 CARTITUDE-1 study presented at ASH 2020 show 97 percent overall response rate at median follow-up of 12.4 months
https://www.dana-farber.org/clinical-trials/23-575
An Open-label Multicenter Phase 1b-2 Study of Elacestrant in Combination with Abemaciclib in Women...
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain...
https://www.biospace.com/immpact-bio-awarded-8-million-cirm-grant-for-phase-1b-2-development-of-impt-514-a-cd19-cd20-bispecific-car-t-cell-therapy-for-refractory-lupus-nephritis-and-systemic-lupus-erythematosus
ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20...
Feb 28, 2024 - ImmPACT Bio Awarded $8 Million CIRM Grant for Phase 1b/2 Development of IMPT-514, a CD19/CD20 Bispecific CAR T-Cell Therapy for Refractory Lupus Nephritis and...
https://www.biospace.com/transgene-presents-e-poster-outlining-detailed-results-from-the-phase-1b-2-trial-of-tg4001-in-combination-with-avelumab-in-advanced-hpv-positive-cancers-at-sitc-2020
Transgene Presents E-Poster Outlining Detailed Results from the Phase 1b/2 Trial of TG4001 in...
Nov 10, 2020 - Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5%
https://www.mayo.edu/research/clinical-trials/cls-20111959
A Phase 1B Dose-escalation Study Of TRC105 In Combination With Pazopanib In Patients With Advanced...
Learn more about services at Mayo Clinic.
https://www.biospace.com/applied-molecular-transport-presents-additional-positive-data-from-oral-amt-101-phase-1b-in-ulcerative-colitis-at-ecco-21-virtual-congress
Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in...
Jul 9, 2021 - Applied Molecular Transport Inc. today announced additional Phase 1b data for oral AMT-101 in ulcerative colitis (UC) patients.
https://finviz.com/news/134732/i-mab-completes-enrollment-in-planned-phase-1b-dose-expansion-study-for-givastomig-in-combination-with-immunochemotherapy-in-patients-with-1l-gastric-cancers
I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination...
Stock screener for investors and traders, financial visualizations.
https://www.biospace.com/press-releases/novo-nordisk-successfully-completes-phase-1b-2a-trial-with-subcutaneous-amycretin-in-people-with-overweight-or-obesity
Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with...
https://www.biospace.com/ligand-pharmaceuticals-inc-to-present-results-of-lgd-6972-phase-1b-trial-at-american-diabetes-association-75th-scientific-sessions-on-june-7th-and-ho
Ligand Pharmaceuticals Inc. To Present Results Of LGD-6972 Phase 1b Trial At American Diabetes...
https://www.biospace.com/deciphera-pharmaceuticals-presents-preliminary-data-from-phase-1b-2-study-of-rebastinib-in-combination-with-paclitaxel-in-patients-with-advanced-endometrial-cancer-at-the-asco-2020-virtual-scientific-program
Deciphera Pharmaceuticals Presents Preliminary Data from Phase 1b/2 Study of Rebastinib in...
May 29, 2020 - Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2...
https://www.businesswire.com/news/home/20260505524502/en/Sensei-Biotherapeutics-Doses-First-Patient-in-Phase-1b2-Trial-of-PIKTOR-in-HRHER2--Advanced-Breast-Cancer
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced...
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company, announced today that the first patient was dosed in Study FTH-PIK-101 (N...
https://www.businesswire.com/news/home/20200127005215/en/AVEO-Oncology-and-Biodesix-Announce-Results-from-Phase-1b-Study-of-Ficlatuzumab-Gemcitabine-and-Nab-paclitaxel-in-Advanced-Pancreatic-Cancer
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and...
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the presentation of results from an investigator-sponsored Phase 1b trial of ficlatuzumab, AV...
https://www.biospace.com/synthetic-biologics-inc-announces-positive-topline-results-from-phase-1b-trial-of-syn-004-to-protect-the-microbiome-and-prevent-c-difficile-infecti
Synthetic Biologics, Inc. Announces Positive Topline Results From Phase 1b Trial Of SYN-004 To...
https://menafn.com/1109864847/Eledon-Pharmaceuticals-To-Host-A-Conference-Call-To-Discuss-Updated-Data-From-The-Ongoing-Phase-1B-Trial-Of-Tegoprubart-In-Kidney-Transplantation-Being-Presented-At-The-World-Transplant-Congress-2025
Eledon Pharmaceuticals To Host A Conference Call To Discuss Updated Data From The Ongoing Phase 1B...
Eledon Pharmaceuticals To Host A Conference Call To Discuss Updated Data From The Ongoing Phase 1B Trial Of Tegoprubart In Kidney Transplantation Being...
host a conference call